Free tool
FAERS Monitor: Trudhesa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213436 or its brand name (Trudhesa, Dihydroergotamine Mesylate). Reports on generic versions are filed under their own applications.
Reports
1,336
Serious
685
51% of reports
Hospitalization
155
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective591
- nausea395
- off label use367
- hyperhidrosis356
- nightmare339
- sedation339
- product use in unapproved indication293
- nephrolithiasis252
- migraine110
- dyspnoea88
- nasal congestion81
- headache64
- treatment failure58
- diarrhoea52
- dizziness51
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 17 |
| 2005 | 16 |
| 2006 | 24 |
| 2007 | 24 |
| 2008 | 20 |
| 2009 | 15 |
| 2010 | 18 |
| 2011 | 26 |
| 2012 | 26 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 9 |
| 2017 | 18 |
| 2018 | 14 |
| 2019 | 26 |
| 2020 | 20 |
| 2021 | 67 |
| 2022 | 172 |
| 2023 | 237 |
| 2024 | 181 |
| 2025 | 181 |
| 2026 | 219 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,823 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sedationSignal | 339 | 206.4 | 188.1 | 68,292 |
| nightmareSignal | 339 | 155.8 | 142.0 | 51,549 |
| nephrolithiasisSignal | 252 | 87.0 | 77.8 | 21,258 |
| hyperhidrosisSignal | 356 | 43.6 | 39.9 | 14,835 |
| nasal congestionSignal | 81 | 21.7 | 17.6 | 1,583 |
| product use in unapproved indicationSignal | 293 | 18.6 | 16.8 | 4,924 |
| migraineSignal | 110 | 18.2 | 15.2 | 1,773 |
| treatment failureSignal | 58 | 11.0 | 8.6 | 521 |
| nauseaSignal | 395 | 7.9 | 7.2 | 2,449 |
| drug ineffectiveSignal | 591 | 7.1 | 6.6 | 3,273 |
| off label useSignal | 367 | 6.6 | 6.0 | 1,813 |
| dyspnoeaSignal | 88 | 2.4 | 2.0 | 76 |
| dizziness | 51 | 1.6 | 1.2 | 11 |
| headache | 64 | 1.6 | 1.3 | 15 |
| diarrhoea | 52 | 1.3 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.